Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344507 | 0.89 | EPHX2 (0.44) | EPHX2LIPERBP4GPR119 | |
| SCHEMBL6346315 | 0.83 | EPHX2 (0.39) | EPHX2CYP2C9CYP2J2LIPESCD | |
| SCHEMBL6347346 | 0.82 | TRPM8 (0.48) | MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL4837016 | 0.80 | POLB (0.49) | — | |
| SCHEMBL6347296 | 0.79 | SIGLEC9 (0.49) | EPHX2CYP2C9GPR119MAPTL3MBTL1 | |
| SCHEMBL6346836 | 0.77 | KDM4E (0.42) | EPHX2CYP2C9CYP2J2MAPTL3MBTL1 | |
| SCHEMBL6346782 | 0.76 | CYP3A4 (0.39) | EPHX2SCDMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL6344202 | 0.76 | GPR119 (0.42) | EPHX2LIPESCDGPR119USP30 | |
| SCHEMBL6343706 | 0.74 | EPHX2 (0.40) | EPHX2CYP2C9CYP2J2SCDMAPT | |
| SCHEMBL4713304 | 0.74 | GPR119 (0.62) | EPHX2GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | EPHX2 1259/4885CYP2C9 2462/4885CYP2J2 2186/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | EPHX2 1576/4885CYP2C9 2235/4885CYP2J2 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.